AI and Machine Learning Deployed for Real-time Medical Literature Surveillance

The innovative start-up Biologit, created by Nicole Baker and Bruno Ohana in 2021, has been revolutionizing the way companies carry out the surveillance of medical and health product literature.

Get a Free Speed Boost on Your Internet Connection: The One Surprising Trick Virgin Media Users Need to Try Now

Nicole Baker, with her deep understanding of immunology, expresses the significance of monitoring such products, stressing, "Patient safety is paramount, and is ensured by incessant scrutiny for any adverse outcomes from health products."

The implications of adverse events are profound, leading to hospitalizations and severe health complications, a concern taken seriously by global health regulators.

Advancing Drug Safety Through Technology ️

At the helm of Biologit, Baker, alongside technology connoisseur Bruno Ohana, brings a wealth of experience from the biotech and pharma sectors to the table. Their primary aim is to integrate AI in safeguarding patients by easing the detection of adverse reactions throughout all stages of drug development and beyond.

Is your Wi-Fi speed being murdered? The common mistake all BT broadband users must check today

Biologit's multifaceted solutions encompass the full spectrum of life sciences, melding insightful domain expertise with state-of-the-art tech. "Our mission is to provide comprehensive active safety surveillance solutions that are vital for patient care," stakes Baker.

️ Conceived and Cultivated From Scratch

The company, with its conceptual seeds planted at Trinity College Dublin, has grown under various Enterprise Ireland programs, reflecting Baker's entrepreneurial journey through New Frontiers in 2019 and Big Ideas 2020.

From the beginning, Biologit has collaborated with early users to tailor its debut product, Biologit MLM-AI, a tool devised to precisely address the urgent needs of the industry.

A Disturbing Bug in a Popular Android App Has Led Google to Take Drastic Action: Check Your Phone Now!

"We crafted every detail, from UI to AI, with direct input from domain experts, ensuring a profound understanding of AI's application for the most crucial user needs, while respecting strict compliance standards," reveals Baker.

Biologit's platform boasts an impressive database with over 45 million citations, continuously updated, offering a rich resource for scientific inquiry and search efficiency.

Scaling New Heights

The past year saw MLM-AI's launch, with Baker and Ohana focusing on initiating a formidable customer base. "Our efforts now pivot towards aggressive customer acquisition and growth," shared Baker, remarking on their strategy abroad and the increasing global user base.

Phones LTD Offers Samsung S23 Ultra EE Deals with Complimentary Galaxy Watch5

Baker views the abundant customer onboarding and their robust, multicultural team as a fortuity in the journey to propel Biologit into a prominent future position.

Optimistic about growth, Biologit is on track to substantially expand its team, following a successful funding round that garnered a €2m investment (approximately £1.72m) from Enterprise Ireland, a testament to their potential and operational expansion plans.

For Baker, prioritizing the myriad crucial tasks remains her challenge. In contrast, Ohana's machine learning expertise stirs excitement within the team. "We've navigated an array of engaging challenges, learning and adapting at every turn, all while upholding our commitment to security, compliance, and innovation for our clients," emphasizes Ohana.

Discover the Samsung S23 Ultra EE Deals with Phones LTD: Don't Miss the Chance to Receive a Complimentary Galaxy Watch5!

We thank you for reading and encourage you to subscribe to our Telegram channel for more updates. For additional news, please check out our Home page.